Citi analyst Patrick Donnelly upgraded Agilent to Buy from Neutral with a price target of $150, up from $135. The analyst sees an improved landscape for the nucleic acid solutions, particularly in fiscal 2025 and 2026, and says the company’s second half of 2024 ramp “screens de-risked” following the fiscal 2024 guidance cut on the Q2 call. The firm says Agilent’s new investment will create a Train C and D, and is expected to double the revenue capacity of NASD to just under a $1B run rate upon manufacturing at full capacity.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on A:
- Agilent price target raised to $130 from $126 at Evercore ISI
- Agilent names Bret DiMarco chief legal officer
- Dynatrace initiated, U.S. Bancorp downgraded: Wall Street’s top analyst calls
- Agilent downgraded to Peer Perform from Outperform at Wolfe Research
- Agilent price target raised to $140 from $134 at BofA